Panacea Venture Healthcare Fund

James Huang founded Panacea Venture in 2017. He previously spent over a decade at Kleiner Perkins Caufield & Byers, where he built and led the firm's life-sciences practice in China. Huang is a trained scientist with deep experience in cross-border biopharma deal-making, particularly between US- and China-based drug-development companies.

The firm invests in early-stage therapeutics, medical devices, and molecular diagnostics companies. Its portfolio is concentrated on first-in-class and best-in-class drug candidates, typically at the Series A and B stages, where the clinical risk is high but the potential for outsized returns exists. Panacea leads or co-leads syndicates and focuses on companies that can benefit from both US and Asian market access.

Panacea Venture is a traditional venture capital firm, structured as a closed-end fund manager raising capital from institutional limited partners. It is not a family office. The firm operates like a specialist healthcare VC, with a GP-LP structure and a dedicated investment committee chaired by James Huang.

Panacea runs a rare dual-hub model: its deal-sourcing and portfolio-support teams sit in Shanghai and San Francisco, while the fund vehicle itself is domiciled in the Cayman Islands. This legal and operational architecture allows the firm to invest in China-based biotech startups and shepherd them toward US clinical and capital-market milestones at a time when most Western generalist VCs have exited China healthcare completely.

Panacea closed its second fund in 2021. The exact fund size has not been publicly confirmed by the firm, though database records suggest a raise in the low hundreds of millions of dollars. That scale is appropriate for a specialist healthcare venture firm making concentrated, capital-intensive biotech investments.

Yes. Panacea routinely co-leads or participates in syndicates alongside other specialist healthcare investors. This co-investment approach is standard for early-stage biotech, where syndicate formation helps diversify binary clinical risk across multiple institutional backers.

The firm is legally domiciled in Grand Cayman, Cayman Islands. This domicile is common for Asia-focused venture funds and allows the firm to pool capital from international LPs under a neutral, well-tested legal framework. Combined with operating teams in Shanghai and San Francisco, the Cayman structure enables cross-border investment flows that a US- or China-only entity would find more difficult to execute under current regulatory conditions.